Bids are rising in the pharmaceutical industry.
Three heavyweights in the sector, Sanofi, Johnson & Johnson (J&J) and Amgen covet the biotech Horizon Therapeutics, valued at $23 billion.
Regulations in Ireland, where the company is headquartered, forced Sanofi and Amgen to declare on Friday that they would make a "cash" offer.
Prime Macron 2022: conditions, amount, date of payment... how does it work?
J&J, which was also in talks with Horizon, finally backtracked on Saturday, saying it "
reserved the right
" to make an offer within the next six months.
Horizon gave them until January 10 to declare their candidacy.
If any of them got their way, it would probably be the biggest deal of the year in the industry.
Anticipating patent losses
Horizon Therapeutics, specializing in rare and autoimmune diseases, which has itself grown through external growth, would be a good catch.
Its biggest drug, Tepezza, marketed mainly in the United States, is prescribed to treat thyroid ophthalmopathy…
This article is for subscribers only.
You have 69% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
I ENJOY IT